Accarb

Main information

  • Trade name:
  • Accarb 50 mg Tablet
  • Dosage:
  • 50 mg
  • Pharmaceutical form:
  • Tablet
  • Units in package:
  • Blister pack, Aluminium/Aluminium foil., 30 tablets
  • Class:
  • Prescription
  • Prescription type:
  • Prescription
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug
  • Manufactured by:
  • Bayer AG

Documents

Localization

  • Available in:
  • Accarb 50 mg Tablet
    New Zealand
  • Language:
  • English

Therapeutic information

  • Therapeutic indications:
  • Indicated for the additional treatment of insulin dependent and non-insulin dependent diabetes mellitus in association with diet.

Other information

Status

  • Source:
  • Medsafe - Medicines Safety Authority - New Zealand
  • Authorization number:
  • 13270
  • Authorization date:
  • 15-08-2007
  • Last update:
  • 27-09-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

NEWZEALANDCONSUMER MEDICINEINFORMATION

ACCARB

AcarboseTablets50mg&100mg

Whatisinthisleaflet

Thisleafletanswerssomecommon

questionsaboutACCARB.

Itdoesnotcontainalltheavailable

information.Itdoesnottakethe

placeoftalkingtoyourdoctoror

pharmacist.

Allmedicineshaverisksand

benefits.Yourdoctorhasweighed

therisksofyoutakingACCARB

againstthebenefitstheyexpectit

willhaveforyou.

Ifyouhaveanyconcernsabout

takingthismedicine,askyour

doctororpharmacist.

Keepthisleafletwiththe

medicine.Youmayneedtoreadit

again.

WhatACCARBis

usedfor

ACCARBtabletscontaintheactive

ingredientacarbose.Theyareused

forthetreatmentofdiabetes(both

type1,insulin-dependentdiabetes

andtype2,non-insulin-dependent

diabetes)inassociationwithdiet.

ACCARBhelpstocontrolyour

bloodsugarlevelsinconjunction

withdiet,exercise,weightlossand

othermeasuresbyslowingdown

thedigestionofcarbohydrates

(complexsugars)fromyourdiet.

Thisreducestheabnormallyhigh

bloodsugarlevelsthatoccurafter

eachmeal.

Askyourdoctorifyouhaveany

questionsaboutwhythis

medicinehasbeenprescribedfor

you.

Yourdoctormayhaveprescribedit

foranotherreason.

ACCARBisnotknowntobe

Thismedicineisavailableonlywith

adoctor’sprescription.

Thereisnotenoughinformationto

recommendtheuseofthismedicine

forchildrenundertheageof18

years.

Beforeyoutake

ACCARB

Whenyoumustnottake

it

DonottakeACCARBifyouhave

anallergyto:

anymedicinecontaining

acarbose

anyoftheingredientslisted

attheendofthisleaflet.

Someofthesymptomsofan

allergicreactionmayinclude:

shortnessofbreath;wheezingor

difficultybreathing;swellingofthe

face,lips,tongueorotherpartsof

thebody;rash,itchingorhiveson

theskin.

Donottakethismedicineifyou

have:

severekidneyproblems

long-termboweldisorders

associatedwithdigestion

andabsorptionproblems

aconditionthatmaybe

worsenedbyincreasedgas

formationinthebowel

(suchasRoemheld’s

syndrome,majorhernias,

intestinalobstructionsor

intestinalulcers,ulcerative

colitisorCrohn’sdisease).

Donottakethismedicineafter

theexpirydateprintedonthe

packorifthepackagingistornor

showssignsoftampering.

Ifithasexpiredorisdamaged,

returnittoyourpharmacistfor

Ifyouarenotsurewhetheryou

shouldstarttakingthismedicine,

talktoyourdoctor.

Beforeyoustarttotake

it

Tellyourdoctorifyouhave

allergiestoanyothermedicines,

foods,preservativesordyes.

Tellyourdoctorifyouhaveor

havehadanyofthefollowing

medicalconditions:

kidneyproblems

liverproblems

bowel,digestionor

absorptionproblems.

Tellyourdoctorifyouare

pregnantorplantobecome

pregnantorarebreast-feeding.

Yourdoctorcandiscusswithyou

therisksandbenefitsinvolved.

Ifyouhavenottoldyourdoctor

aboutanyoftheabove,tell

him/herbeforeyoustarttaking

ACCARB.

Takingothermedicines

Tellyourdoctororpharmacistif

youaretakinganyother

medicines,includinganythatyou

getwithoutaprescriptionfrom

yourpharmacy,supermarketor

healthfoodshop.

SomemedicinesandACCARBmay

interferewitheachother.These

include:

digoxin,amedicinetotreat

chronicheartfailureor

irregularheartrhythms

oralneomycinantibiotic

cholestyramine,amedicine

usedtohelpreduce

cholesterol,relieveitching

duetobile,orrelievesome

causesofdiarrhoea

intestinaladsorbentssuch

ascharcoal

digestiveenzyme

preparationssuchas

ancrease™,Creon™.

Thesemedicinesmaybeaffected

byACCARBormayaffecthowwell

itworks.Youmayneeddifferent

amountsofyourmedicines,oryou

mayneedtotakedifferent

medicines.

Ifyouareusingothermedicines

fordiabetessuchasinsulin,

metforminorsulfonylureasandtend

tohavelowbloodsugarlevels,tell

yourdoctorbeforeusingACCARB.

Youshouldavoidtakingcane

sugar(sucrose)andproducts

containingsugar.

Theymaycausestomach

discomfortorevendiarrhoeaif

takenwhileyouareonACCARB

tablets.

Yourdoctorandpharmacisthave

moreinformationonmedicinesto

becarefulwithoravoidwhiletaking

thismedicine.

Howtotake

ACCARB

Followalldirectionsgiventoyou

byyourdoctororpharmacist

carefully.

Theymaydifferfromtheinformation

containedinthisleaflet.

Ifyoudonotunderstandthe

instructionsonthepack,ask

yourdoctororpharmacistfor

help.

Howmuchtotake

Togainthemaximumbenefitfrom

ACCARBitisimportantthatyou

followtheprescribeddietaswellas

takingtheexactdoseofACCARB

prescribedbyyourdoctor.Thiswill

helpcontrolyourbloodsugarlevels

andreduceside-effectsfrom

ACCARB.

WhenandHowtotakeit

Takethetabletsasprescribedby

yourdoctor.Thiswillnormallybe

oneortwotabletstakenwith

breakfast,lunchanddinner.

Whenyoufirststartyourtreatment,

youtakeyourtabletsonceortwice

aday,beforeincreasingyourdose

tothreetimesaday.

Chewthetabletswiththefirstfew

mouthfulsoffood.Ifyouprefernot

tochewthetabletsthenswallow

themwholewithalittleliquid

immediatelybeforethemeal.

Theaverageadultdoseisone

ACCARB100mgtablettakenwith

breakfast,lunchanddinner.

Takeyourmedicineataboutthe

sametimeseachday.

Takingitatthesametimeseach

daywillhavethebesteffect.Itwill

alsohelpyourememberwhento

takeit.

Howlongtotakeit

Continuetakingyourmedicine

foraslongasyourdoctortells

you.

Thismedicinehelpstocontrolyour

condition,butdoesnotcureit.Itis

importanttokeeptakingyour

medicineevenifyoufeelwell.

Ifyouforgettotakeit

IfyouforgettotakeACCARBat

thetimeyouaresupposedto,do

nottakethetabletsbetween

meals.Waituntilitistimeforyou

totakeyournextdoseandtake

ACCARBwithyourmealand

continueasbefore.

Donottakeadoubledoseto

makeupforthedosethatyou

missed.

Thismayincreasethechanceof

yougettinganunwantedsideeffect.

Ifyouarenotsurewhattodo,

askyourdoctororpharmacist.

Ifyouhavetroublerememberingto

takeyourmedicine,askyour

pharmacistforsomehints.

Ifyoutaketoomuch

(overdose)

Avoidfoodordrinkscontaining

carbohydratesandimmediately

telephoneyourdoctororthe

NationalPoisonsInformation

Centre(0800POISONor0800764

766)foradvice,orgotoAccident

andEmergencyatthenearest

anyoneelsemayhavetakentoo

muchACCARB.Dothisevenif

therearenosignsofdiscomfort

orpoisoning.Youmayneed

urgentmedicalattention.

WhenACCARBistakenwithdrinks

and/ormealscontaining

carbohydrates,overdosagecan

leadtodiarrhoeaandother

intestinalsymptomssuchas

flatulence(wind)andabdominal

cramps.

Whileyouaretaking

ACCARB

Thingsyoumustdo

Ifyouareabouttobestartedon

anynewmedicine,remindyour

doctorandpharmacistthatyou

aretakingACCARB.

Tellanyotherdoctors,dentists,

andpharmacistswhotreatyou

thatyouaretakingthismedicine.

Ifyouaregoingtohavesurgery,

tellthesurgeonoranaesthetist

thatyouaretakingthismedicine.

Itmayaffectothermedicinesused

duringsurgery.

Ifyoubecomepregnantwhile

takingthismedicine,tellyour

doctorimmediately.

Ifyouareabouttohaveany

bloodtests,tellyourdoctorthat

youaretakingthismedicine.

Itmayinterferewiththeresultsof

sometests.

Keepallofyourdoctor’s

appointmentssothatyour

progresscanbechecked.

Yourdoctormaydosometests

(suchasbloodteststocheckyour

bloodsugarlevelsandliver

function)fromtimetotimetomake

surethemedicineisworkingandto

preventunwantedsideeffects.

Thingsyoumustnotdo

DonottakeACCARBtotreatany

othercomplaintsunlessyour

doctortellsyouto.

Donotgiveyourmedicineto

anyoneelse,eveniftheyhave

thesameconditionasyou.

Donotstoptakingyourmedicine

orchangethedosagewithout

checkingwithyourdoctor.

Thingstobecarefulof

Treatinghypoglycaemia

(“hypos”orlowblood

sugar)

Youmayalsobereceivingother

medicinesforyourdiabetes.If

ACCARBisprescribedforyouin

additiontosulfonylureasor

metformintocontrolyourdiabetes,

yourdoctormayneedtoadjustthe

dosagesofyourmedicinestoavoid

theoccurrenceof“hypos”.

WhentakingACCARBtogetherwith

thesemedicines,donottreata

"hypo"withordinarysugar

(sucrose).Itwillnotworkfast

enough.Instead,youshouldtake

someGLUCOSE(alsoknownas

dextrose)orhoney.Glucoseis

availableintablets,syruporsweets,

whichshouldbeavailablefromyour

localpharmacy.

Becarefuldrivingoroperating

machineryuntilyouknowhow

ACCARBaffectsyou.

Whenusedwithsomeother

medicinesfordiabetes, “hypos”or

lowbloodsugarordizzinessmay

occurinsomepeople.Ifyouhave

anyofthesesymptoms,donot

drive,operatemachineryordo

anythingelsethatcouldbe

dangerous.

Sideeffects

Tellyourdoctororpharmacistas

soonaspossibleifyoudonot

feelwellwhileyouaretaking

ACCARB.

Thismedicinehelpsmostpeople

withdiabetes,butitmayhave

unwantedsideeffectsinsome

people.Allmedicinescanhaveside

effects.Sometimestheyare

serious,mostofthetimetheyare

not.Youmayneedmedical

attentionifyougetsomeoftheside

effects.

Donotbealarmedbythe

followinglistsofsideeffects.

Youmaynotexperienceanyof

Askyourdoctororpharmacistto

answeranyquestionsyoumay

have.

Tellyourdoctororpharmacistif

younoticeanyofthefollowing

sideeffectsandtheyworryyou:

increasedflatulence(wind)

abdominalpainor

discomfort

diarrhoea.

Theabovelistincludessomeofthe

morecommonsideeffectsofyour

medicine.Oftenthesesymptoms

willdisappearifyoucontinue

treatmentandkeeptoyour

prescribeddiet.Ifyoueatordrink

productscontainingcanesugar

(sucrose),thesesideeffectscould

getworse.

Tellyourdoctororpharmacistif

younoticeanyofthefollowing

sideeffectsandtheyworryyou:

nausea

vomiting

indigestion.

Theabovelistincludessomeofthe

lesscommonsideeffects.

Ifyouareconcerned,oranyof

yoursymptomsaresevere,talk

toyourdoctorassoonas

possible.

WhenACCARBistakentogether

withothermedicinesfordiabetes,

suchassulfonylureasormetformin,

hypoglycemia(“hypos”orlowblood

sugarlevels)canoccur.Symptoms

ofhypoglycemiamayinclude

sweating,weakness,hunger,

dizziness,trembling,headache,

flushingorpaleness,numbness,a

fast,poundingheartbeat.Letyour

doctorknowifyounoticeanyofthe

above,asyourdoctormayneedto

adjustthedosagesofyour

medicines.

Ifanyofthefollowinghappen,

tellyourdoctorimmediatelyor

gotoAccidentandEmergencyat

yournearesthospital:

jaundice(yellowingofthe

skinoreyes)

severestomachor

abdominalpain

swellingoftheface,lips,

tongueorotherpartsofthe

body

shortnessofbreath,

wheezingortroubled

breathing.

Theabovelistincludesveryserious

sideeffects.Youmayneedurgent

medicalattentionorhospitalisation.

Tellyourdoctororpharmacistif

younoticeanythingthatis

makingyoufeelunwell.

Othersideeffectsnotlistedabove

mayoccurinsomepeople.

Somesideeffectsforexample,

changesinnumbersofbloodcells,

inflammationoftheliver(hepatitis),

changesinliverenzymelevels,can

onlybefoundwhenyourdoctor

doestestsfromtimetotimeto

checkyourprogress.

AfterusingACCARB

Storage

Keepyourtabletsinthepack

untilitistimetotakethem.

Ifyoutakethetabletsoutofthe

packtheymaynotkeepwell.

Keepyourtabletsinacooldry

placewherethetemperaturestays

below25°C.

DonotstoreACCARBoranyother

medicineinthebathroomorneara

sink.Donotleaveitonawindowsill

orinthecar.

Heatanddampnesscandestroy

somemedicines.

Keepitwherechildrencannot

reachit.

Alockedcupboardatleastone-and-

ahalfmetresabovethegroundisa

goodplacetostoremedicines.

Disposal

Ifyourdoctortellsyoutostop

takingthismedicineortheexpiry

datehaspassed,askyour

pharmacistwhattodowithany

medicinethatisleftover.

Productdescription

Whatitlookslike

ACCARBtabletsareavailableina

blisterpackof90tabletsintwo

strengths.

ACCARB50mgTablets:White

roundtablet,debossedwith'AA'

breakline'50'ononesideand'G'on

thereverse,approximately7mmin

diameter.

ACCARB100mgTablets:White

roundtablet,debossedwith'AA'

breakline'100'ononesideand'G'

onthereverse,approximately9mm

indiameter.

Ingredients

ACCARB50contains50mgof

acarboseastheactiveingredient.

ACCARB100contains100mgof

acarboseastheactiveingredient.

ACCARBtabletsalsocontain:

MicrocrystallineCellulose

(PH102)

DriedMaizeStarch

ColloidalAnhydrousSilica

MagnesiumStearate.

Thismedicinedoesnotcontain

lactose,sucrose,gluten,tartrazine

oranyazodyes.

Ifyouwanttoknow

more

Shouldyouhaveanyquestions

regardingthisproduct,please

contactyourpharmacistordoctor.

Whosuppliesthis

medicine

DistributedinNewZealandby:

MylanNewZealandLtd,

POBox11183,

Ellerslie,

Auckland.

Telephone:(09)5792792

DateofInformation

1August2012

(Basedondatasheetdated

25July2012)

Document Outline

3-1-2019

Loblaw Companies Limited recalls Life at Home 50 Count Indoor LED Microdot Icicle Lights

Loblaw Companies Limited recalls Life at Home 50 Count Indoor LED Microdot Icicle Lights

Due to a potential manufacturing defect the lights may overheat, posing a burn and fire hazard.

Health Canada

21-12-2018

Funky Chunky, Llc Issues Allergy Alert on Undeclared Almond and Cashew Tree-Nut in 10 Oz. Nutty Choco Pop Found in Chocolate Popcorn Gift Box, Holiday Crowd Pleaser and Crowd Pleaser Gifts

Funky Chunky, Llc Issues Allergy Alert on Undeclared Almond and Cashew Tree-Nut in 10 Oz. Nutty Choco Pop Found in Chocolate Popcorn Gift Box, Holiday Crowd Pleaser and Crowd Pleaser Gifts

Funky Chunky, LLC of Eden Prairie, MN is recalling 10 oz Nutty Choco Pop Gift Box, 50 oz. Holiday Crowd Pleaser and 50 oz. Crowd Pleaser, because it may contain undeclared Almond and Cashew Tree Nut. People who have an allergy or severe sensitivity to Almonds and Cashews run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

29-11-2018

ANSES Newsletter in English - N°50 - November 2018

ANSES Newsletter in English - N°50 - November 2018

France - Agence Nationale du Médicament Vétérinaire

22-11-2018

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Published on: Wed, 21 Nov 2018 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Monteban® G100 for ducks. Monteban® G100, containing narasin, is intended for the prevention of coccidiosis in ducks for fattening at a dose range of 60–70 mg/kg of complete feed. Narasin from Monteban® G100 is safe for ducks for fattening at a level of 70 mg/kg complete feed...

Europe - EFSA - European Food Safety Authority Publications

21-11-2018

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Published on: Tue, 20 Nov 2018 The feed additive Monteban® G100, containing the active substance narasin, an ionophore anticoccidial, is intended to control coccidiosis in chickens for fattening at a dose of 60–70 mg/kg complete feed. Narasin is produced by fermentation. Limited data on the taxonomic identification of the production strain did not allow the proper identification of strain NRRL 8092 as Streptomyces aureofaciens. The FEEDAP Panel cannot conclude on the absence of genetic determinants for ...

Europe - EFSA - European Food Safety Authority Publications

19-11-2018

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

One lot each of Option Family Sunscreen Lotion SPF 50 and Personnelle Sport Sunscreen Lotion SPF 50 have been voluntarily recalled by Empack Spraytech Inc. because of bacterial contamination.

Health Canada

15-11-2018

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Published on: Wed, 14 Nov 2018 The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active substances, the metabolic pathways in the chicken are similar to those in the turkey and rat. Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC)...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Published on: Wed, 07 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of the additive Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials. It is a family of mixtures combining the four lanthanides lanthanum (La), europium (Eu), gadolinium (Gd) and/or terbium (Tb) in different proportions as their 1,4‐benzene dicarboxylate complexes, used as a taggant in plastics for authentication and ...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos (hop strobiles) when used as a sensory feed additive for all animal species. The additive is specified to containing 40% beta acids and less than 0.2% alpha acids. Known substances of conce...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

3-8-2018

Scientific guideline:  Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

25-7-2018

AMPI Recalls Limited Amount of Dry Whey Powder Because of Possible Health Risk

AMPI Recalls Limited Amount of Dry Whey Powder Because of Possible Health Risk

Associated Milk Producers Inc. (AMPI) of New Ulm, Minn., is recalling dry whey powder packaged in 50-pound and 25-kg bags that were produced at the cooperative’s Blair, Wis., dry whey plant from May 1-5, 2018; May 24-29, 2018; June 2-5, 2018; and June 7-14, 2018 due to the potential to be contaminated with Salmonella. This is a precautionary recall. All products shipped to the marketplace tested negative for Salmonella.

FDA - U.S. Food and Drug Administration

17-7-2018

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

FDA - U.S. Food and Drug Administration

31-5-2018

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint.

FDA - U.S. Food and Drug Administration

7-12-2018


Acarbose: List of nationally authorised medicinal products - PSUSA/0000017/201803

Acarbose: List of nationally authorised medicinal products - PSUSA/0000017/201803

Acarbose: List of nationally authorised medicinal products - PSUSA/0000017/201803

Europe - EMA - European Medicines Agency

26-11-2018

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009.  https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https://go.usa.gov/xPHdn 

FDA - U.S. Food and Drug Administration

19-9-2018

Targretin (Eisai GmbH)

Targretin (Eisai GmbH)

Targretin (Active substance: bexarotene) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6098 of Wed, 19 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/326/T/50

Europe -DG Health and Food Safety

4-6-2018

Eliquis (Bristol-Myers Squibb/Pfizer EEIG)

Eliquis (Bristol-Myers Squibb/Pfizer EEIG)

Eliquis (Active substance: apixaban) - Centralised - 2-Monthly update - Commission Decision (2018)3616 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2148/II/50

Europe -DG Health and Food Safety